MUMBAI, India and BALTIMORE, Md. — Pharma major Lupin announced the launch of atovaquone oral suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration earlier.

Lupin’s atovaquone oral suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline’s Mepron oral suspension 750 mg/5 mL. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX.